mAbxience
Lugano, Switzerland · mabxience.com
GMP
mAbxience is a vertically integrated biopharmaceutical company that develops and manufactures biologics, with a focus on biosimilars and innovator biologics. It provides end-to-end B2B development and CDMO services from R&D through commercial supply, with sites in Spain and Argentina.
Their website has a general contact form; we send your quote request through it.
What they offer
Biopharmaceutical development
Develops biologics with in-house R&D capabilities, including work specialized in biosimilars and innovator biologics.
CDMO services
Provides integrated development and manufacturing services tailored to client requirements, from research batches to commercial batches.
Cell line development and banking
Supports early-stage programs with cell line development and banking activities.
Analytical development
Develops analytical methods and capabilities to support development, validation, and manufacturing.
Process development
Develops robust and scalable processes for biopharmaceutical programs.
Formulation development
Develops formulations to support clinical and commercial supply.
Demo runs
Performs demo runs as part of early-stage development programs.
Clinical manufacturing
Produces clinical batches under GMP conditions.
Tech transfer and manufacturing readiness
Supports technology transfer and readiness for manufacturing scale-up and transfer.
Process validation and analytical validation
Carries out validation work to support regulatory and manufacturing requirements.
cGMP manufacturing and commercial supply
Manufactures biologics for commercial supply and market needs.
Quality and regulatory support
Provides quality and regulatory support across development and manufacturing activities.
What they work on
- Modalities
- Antibody, Bispecific, ADC, Cell therapy, Vaccine, Biosimilar
- Assays and studies
- analytical development, analytical validation, process validation
- Instruments and platforms
- single-use bioreactors
- Scale and capacity
- 3L-200L small scale GMP production, 200L clinical batches, 2L to 4,000L bioreactors, 6,000L bioreactors coming soon, 12,000L batches coming soon, combined capacity of 50,000L, from 50,000L to 74,000L total capacity, 3 production sites, 5 production lines + 1 coming soon
- Turnaround
- IND ready in 12 months · Manufacturing-ready in 18 months
- Type
- CRDMO
- Sites
- Spain, Spain · Argentina, Argentina · Madrid, Spain · Genhelix, Spain · Garín, Argentina · Munro, Argentina
- Quality
- GMP (production plants and small-scale GMP production) · FDA (GMP approval from regulatory agencies at Genhelix site) · EMA (GMP approval from regulatory agencies at Genhelix and Garín sites) · Japan PMDA (GMP approval from regulatory agencies at Genhelix site) · Australia TGA (GMP approval from regulatory agencies at Genhelix site) · Canada (GMP approval from regulatory agencies at Genhelix site) · Saudi Arabia (GMP approval from regulatory agencies at Genhelix and Munro sites) · COFEPRIS (Mexico) (GMP approval from regulatory agencies at Genhelix, Garín and Munro sites) · Russia (GMP approval from regulatory agencies at Genhelix and Munro sites) · Turkish MoH (GMP approval from regulatory agencies at Genhelix site) · ANMAT (Argentina) (GMP approval from regulatory agencies at Garín and Munro sites) · Jordan (GMP approval from regulatory agencies at Munro site) · Turkey (GMP approval from regulatory agencies at Munro site) · Colombia (GMP approval from regulatory agencies at Munro site)
- Serves
- worldwide, Europe, South America
- Address
- biomanufacturing 2014 – 2015 Genhelix: mAbxience Spain R&D center First launch of
- Founded
- 2019
Public records
Similar labs. Intellective Bio, Avid Bioservices, Kemwell Pharma, MYCENAX
Found in a contract services directory. Listing built from mabxience.com. Work here? Claim this listing.